Ocugen (OCGN) Long-Term Deferred Tax (2014 - 2015)

Ocugen (OCGN) reported Long-Term Deferred Tax of $1.1 million for Q3 2015, up 0.86% quarter-over-quarter from $1.0 million in Q2 2015.

Ocugen (OCGN) Long-Term Deferred Tax (2014 - 2015) Analysis & Trends

Ocugen has reported Long-Term Deferred Tax for 2 years, with the latest figure at $1.1 million in Q3 2015.

For the quarter ending Q3 2015, Long-Term Deferred Tax changed N/A year-over-year to $1.1 million; the trailing twelve-month figure through Sep 2015 stood at $1.1 million (changed N/A YoY), and the FY2014 full-year result was $651000.0, changed N/A from the prior year.
Long-Term Deferred Tax for Q3 2015 stood at $1.1 million, up from $1.0 million in the prior quarter.
The five-year high for Long-Term Deferred Tax was $1.1 million in Q3 2015, with the low at $651000.0 in Q4 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Ocugen	411.07 Mn	411.07 Mn	-

Download Data